|
End-of-day quote
Shenzhen S.E.
2026-08-14
|
5-day change | 1st Jan Change | ||
| 11.61 CNY | -0.43% |
|
+4.22% | -4.44% |
| 05-22 | Zhuhai Rundu Pharmaceutical Wins China Approval for Pain Relief Drug | MT |
| 05-19 | China Grants Zhuhai Rundu Pharmaceutical Marketing Approval for Hypertension Drug | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 5.06 | 4.95 | 2 | 1.12 | -0.79 | |||||
Return on Total Capital | 6.91 | 6.77 | 2.65 | 1.45 | -1.03 | |||||
Return On Equity % | 13 | 13.47 | 5.63 | 3.42 | -5.8 | |||||
Return on Common Equity | 13 | 13.47 | 5.63 | 3.42 | -5.8 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 59.76 | 53.63 | 46.97 | 41.48 | 35 | |||||
SG&A Margin | 39.99 | 33.5 | 30.38 | 26.25 | 28.23 | |||||
EBITDA Margin % | 16.67 | 17.16 | 14.18 | 14.66 | 9.74 | |||||
EBITA Margin % | 11.77 | 12.21 | 5.72 | 3.48 | -2.14 | |||||
EBIT Margin % | 11.64 | 12.1 | 5.6 | 3.34 | -2.26 | |||||
Income From Continuing Operations Margin % | 11.75 | 11.33 | 5.18 | 3.37 | -5.4 | |||||
Net Income Margin % | 11.75 | 11.33 | 5.18 | 3.37 | -5.4 | |||||
Net Avail. For Common Margin % | 11.75 | 11.33 | 5.18 | 3.37 | -5.4 | |||||
Normalized Net Income Margin | 7.19 | 7.35 | 2.86 | 1.37 | -2.31 | |||||
Levered Free Cash Flow Margin | -17.4 | -9.42 | -10.41 | 10.65 | 9.36 | |||||
Unlevered Free Cash Flow Margin | -17.31 | -9.1 | -9.63 | 11.48 | 10.06 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.7 | 0.65 | 0.57 | 0.53 | 0.56 | |||||
Fixed Assets Turnover | 1.53 | 1.25 | 1.04 | 0.96 | 1.03 | |||||
Receivables Turnover (Average Receivables) | 7.46 | 7.53 | 6.19 | 5.53 | 5.63 | |||||
Inventory Turnover (Average Inventory) | 1.5 | 1.64 | 1.6 | 1.61 | 1.83 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.91 | 1.6 | 1.94 | 1.69 | 1.6 | |||||
Quick Ratio | 0.98 | 0.82 | 0.96 | 0.81 | 0.85 | |||||
Operating Cash Flow to Current Liabilities | 0.49 | 0.23 | 0.39 | 0.4 | 0.19 | |||||
Days Sales Outstanding (Average Receivables) | 48.94 | 48.5 | 59 | 66.17 | 64.82 | |||||
Days Outstanding Inventory (Average Inventory) | 242.98 | 222.67 | 228.13 | 226.79 | 199.69 | |||||
Average Days Payable Outstanding | 86.85 | 90.04 | 101.6 | 96.07 | 93.36 | |||||
Cash Conversion Cycle (Average Days) | 205.07 | 181.13 | 185.54 | 196.9 | 171.15 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 25.77 | 39.17 | 48.58 | 43.45 | 51.26 | |||||
Total Debt / Total Capital | 20.49 | 28.14 | 32.7 | 30.29 | 33.89 | |||||
LT Debt/Equity | 22.58 | 31.64 | 37.43 | 31.87 | 30.01 | |||||
Long-Term Debt / Total Capital | 17.95 | 22.74 | 25.19 | 22.22 | 19.84 | |||||
Total Liabilities / Total Assets | 41.75 | 47.69 | 47.07 | 47.48 | 48.81 | |||||
EBIT / Interest Expense | 78.15 | 23.83 | 4.49 | 2.5 | -2.03 | |||||
EBITDA / Interest Expense | 114.1 | 34.2 | 11.49 | 11.16 | 8.89 | |||||
(EBITDA - Capex) / Interest Expense | -98.36 | -1.94 | 0.66 | 6.01 | 7.52 | |||||
Total Debt / EBITDA | 1.42 | 1.97 | 3.09 | 2.84 | 4.57 | |||||
Net Debt / EBITDA | 0.18 | 1.04 | 1.94 | 1.67 | 2.37 | |||||
Total Debt / (EBITDA - Capex) | -1.64 | -34.68 | 53.81 | 5.28 | 5.4 | |||||
Net Debt / (EBITDA - Capex) | -0.21 | -18.31 | 33.71 | 3.1 | 2.8 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -5.01 | 15.32 | -5.86 | -8.48 | -0.51 | |||||
Gross Profit, 1 Yr. Growth % | -6.54 | 3.49 | -17.54 | -19.18 | -16.05 | |||||
EBITDA, 1 Yr. Growth % | -2.52 | 18.68 | -22.2 | -4.93 | -33.67 | |||||
EBITA, 1 Yr. Growth % | -9.58 | 19.68 | -55.92 | -43.62 | -161.86 | |||||
EBIT, 1 Yr. Growth % | -9.81 | 19.88 | -56.44 | -44.67 | -168.1 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 2.87 | 11.24 | -56.97 | -40.38 | -259.14 | |||||
Net Income, 1 Yr. Growth % | 2.87 | 11.24 | -56.97 | -40.38 | -259.14 | |||||
Normalized Net Income, 1 Yr. Growth % | -9.44 | 17.93 | -63.39 | -55.9 | -270.63 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 2.71 | 12.07 | -56.52 | -40 | -258.33 | |||||
Accounts Receivable, 1 Yr. Growth % | 0.9 | 26.44 | 4.84 | 0.61 | -7.23 | |||||
Inventory, 1 Yr. Growth % | 11.1 | 31.39 | -5.76 | 6.39 | -10.72 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 67.11 | 25.82 | 2.12 | -3.26 | -10.48 | |||||
Total Assets, 1 Yr. Growth % | 26.14 | 19.74 | -2.59 | -1.53 | -7.52 | |||||
Tangible Book Value, 1 Yr. Growth % | 7.24 | 8.17 | -1.35 | -2.28 | -10.32 | |||||
Common Equity, 1 Yr. Growth % | 7.12 | 7.54 | -1.41 | -2.29 | -9.87 | |||||
Cash From Operations, 1 Yr. Growth % | -17.75 | -34.43 | 27.9 | 22.3 | -50.56 | |||||
Capital Expenditures, 1 Yr. Growth % | 46.64 | -33.13 | -30.67 | -53.45 | -77.89 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 114.42 | -37.57 | 4.06 | -193.22 | -12.31 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 115.74 | -39.35 | -0.38 | -208.62 | -12.65 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 13.74 | -20 | -25 | - | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -6.46 | 4.67 | 4.2 | -7.18 | -4.58 | |||||
Gross Profit, 2 Yr. CAGR % | -14.4 | -1.65 | -7.62 | -18.36 | -17.63 | |||||
EBITDA, 2 Yr. CAGR % | 20.82 | 7.56 | -3.91 | -14.21 | -20.7 | |||||
EBITA, 2 Yr. CAGR % | 18.78 | 4.02 | -27.37 | -50.45 | -41.31 | |||||
EBIT, 2 Yr. CAGR % | 18.69 | 3.98 | -27.74 | -51.21 | -39.01 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 8.42 | 6.98 | -30.82 | -49.35 | -2.59 | |||||
Net Income, 2 Yr. CAGR % | 8.42 | 6.98 | -30.82 | -49.35 | -2.59 | |||||
Normalized Net Income, 2 Yr. CAGR % | 13.69 | 3.34 | -34.29 | -59.88 | -14.11 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 8.98 | 6.86 | -30.52 | -48.92 | -2.53 | |||||
Accounts Receivable, 2 Yr. CAGR % | -8.14 | 12.95 | 15.14 | 2.71 | -3.39 | |||||
Inventory, 2 Yr. CAGR % | 18.32 | 20.82 | 11.28 | 0.13 | -2.54 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 48.6 | 45 | 13.35 | -0.61 | -6.94 | |||||
Total Assets, 2 Yr. CAGR % | 19.97 | 22.9 | 8.01 | -2.06 | -4.58 | |||||
Tangible Book Value, 2 Yr. CAGR % | 8.25 | 7.7 | 3.3 | -1.82 | -6.39 | |||||
Common Equity, 2 Yr. CAGR % | 8.76 | 7.33 | 2.97 | -1.85 | -6.16 | |||||
Cash From Operations, 2 Yr. CAGR % | 16.66 | -26.56 | -8.42 | 25.07 | -22.24 | |||||
Capital Expenditures, 2 Yr. CAGR % | 25.24 | -0.98 | -31.91 | -43.19 | -67.92 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 43.97 | 15.7 | -19.4 | -1.31 | -9.7 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 44.49 | 14.39 | -22.27 | 4.26 | -2.71 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 6.65 | -4.61 | -22.54 | - | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4.46 | 0.3 | 1.03 | -0.21 | -5 | |||||
Gross Profit, 3 Yr. CAGR % | -3.13 | -8.81 | -7.26 | -11.65 | -17.6 | |||||
EBITDA, 3 Yr. CAGR % | 11.51 | 20.1 | -3.45 | -4.41 | -21.33 | |||||
EBITA, 3 Yr. CAGR % | 7.66 | 19.08 | -21.86 | -33.52 | -46.87 | |||||
EBIT, 3 Yr. CAGR % | 7.44 | 19.09 | -22.2 | -34.16 | -45.71 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 9.37 | 9.35 | -21.03 | -34.16 | -25.82 | |||||
Net Income, 3 Yr. CAGR % | 9.37 | 9.35 | -21.03 | -34.16 | -25.82 | |||||
Normalized Net Income, 3 Yr. CAGR % | 4.3 | 15.08 | -26.87 | -42.53 | -35.42 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 8.81 | 9.71 | -21.06 | -33.84 | -25.53 | |||||
Accounts Receivable, 3 Yr. CAGR % | 7.42 | 2.18 | 10.18 | 10.08 | -0.72 | |||||
Inventory, 3 Yr. CAGR % | 25.16 | 22.53 | 11.22 | 9.62 | -3.63 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 46.49 | 40.58 | 29.01 | 7.52 | -4.01 | |||||
Total Assets, 3 Yr. CAGR % | 18.81 | 19.89 | 13.75 | 4.73 | -3.92 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.12 | 8.22 | 4.59 | 1.4 | -4.74 | |||||
Common Equity, 3 Yr. CAGR % | 8.48 | 8.35 | 4.33 | 1.18 | -4.6 | |||||
Cash From Operations, 3 Yr. CAGR % | 8.99 | -3.73 | -11.64 | 0.85 | -8.21 | |||||
Capital Expenditures, 3 Yr. CAGR % | 48.35 | 1.6 | -12.07 | -40.02 | -58.52 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 90.3 | 8.97 | 11.68 | -15.28 | -5.2 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 94.23 | 8.18 | 9.24 | -12.97 | -1.79 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 4.38 | -3.1 | -11.96 | - | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 12.79 | 11.98 | 4.36 | -2.76 | -1.25 | |||||
Gross Profit, 5 Yr. CAGR % | 11.28 | 7.88 | -4.95 | -12.76 | -11.56 | |||||
EBITDA, 5 Yr. CAGR % | 12.83 | 12.5 | 5.07 | 4.98 | -10.85 | |||||
EBITA, 5 Yr. CAGR % | 9.47 | 10.74 | -8.02 | -16.14 | -30.48 | |||||
EBIT, 5 Yr. CAGR % | 9.37 | 10.66 | -8.32 | -16.66 | -29.59 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 9.83 | 11.39 | -8.94 | -19.62 | -14.12 | |||||
Net Income, 5 Yr. CAGR % | 9.83 | 11.39 | -8.94 | -19.62 | -14.12 | |||||
Normalized Net Income, 5 Yr. CAGR % | 9.81 | 11.72 | -13.3 | -24.5 | -22.06 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 3.18 | 4.65 | -9.21 | -19.35 | -14.12 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13.56 | 14.67 | 10.44 | 2.39 | 4.54 | |||||
Inventory, 5 Yr. CAGR % | 32.18 | 29.12 | 19.41 | 13.02 | 5.5 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 30.94 | 37.56 | 32.21 | 22.38 | 13.21 | |||||
Total Assets, 5 Yr. CAGR % | 25.37 | 26.49 | 14.37 | 10.58 | 6.03 | |||||
Tangible Book Value, 5 Yr. CAGR % | 22.75 | 19.37 | 5.58 | 4.09 | 0.05 | |||||
Common Equity, 5 Yr. CAGR % | 22.8 | 19.59 | 6.24 | 4.15 | 0 | |||||
Cash From Operations, 5 Yr. CAGR % | 16.96 | 8.54 | 1.66 | 6.9 | -16.05 | |||||
Capital Expenditures, 5 Yr. CAGR % | 42.59 | 47.23 | 8.64 | -19.48 | -41.25 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 85.43 | 76.87 | 34.96 | 4.74 | 2.66 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 96.7 | 96.42 | 34.66 | 6.6 | 4.39 | |||||
Dividend Per Share, 5 Yr. CAGR % | - | 3.19 | -1.87 | -7.36 | - |
Select your edition
All financial news and data tailored to specific country editions
















